Back to the Annual Review

NCRI is working in partnership with the British Society for Immunology (BSI) to bring the immunology and cancer research communities together. The partnership aims to drive collaborations and address challenges in cancer immunology and immunotherapy through a series of joint initiatives.

The BSI-NCRI Cancer Immunology Group is a multidisciplinary group that drives the joint activities of our organisations to facilitate the interaction of immunologists with cancer researchers and clinicians. For immunotherapies to benefit a wide range of patients, we must advance our understanding of the complex interactions between cancer and the immune system. The most effective and efficient way to achieve this is if immunology and cancer researchers collaborate to answer the key questions.

Professor Ann Ager
Professor of Cellular Immunity and Immunotherapy, Cardiff University, Chair, BSI-NCRI Cancer Immunology Group and Chair, BSI Forum

To drive collaboration between immunologists and cancer researchers, the NCRI is ensuring immunologists are represented in its work. Several immunologists have joined the NCRI Networks, where they will be invited to get involved in the work of the NCRI Groups. Immunologists have taken part in strategy sessions for the NCRI Lung Group, specifically on the topic of immunotherapy.

To share knowledge and research findings with immunologists and cancer researchers, NCRI is working with BSI to contribute to the TrialsWatch feature of the BSI’s open-access journal, Immunotherapy Advances.

Highlighting links between cancer and immunology through events

In conversation with… Fran Balkwill, NCRI Prime, April 2021

Professor Fran Balkwill presented how inflammation is implicated in the development and survival of cancer cells, using ovarian cancer as an example to help the audience better understand the role that inflammation plays in specific cancers. 

Immuno-therapeutics: What’s next? NCRI Festival, November 2021

In this session, speakers discussed how immuno-therapeutics are currently used to treat cancer, what questions remain unanswered, for example treating solid tumours, and some opportunities for this research area including the microbiome.